Avience Biomedi.

Which are the latest news on Avience Biomedi.?

Why is Avience Biomedicals Ltd falling/rising?

As of 05-Sep, Avience Biomedicals Ltd's stock price is rising to 275.00, up 1.66%, driven by strong performance against the Sensex and positive moving averages. Despite a decline in investor participation, the stock remains liquid and shows strong relative strength.

As of 05-Sep, Avience Biomedicals Ltd's stock price is rising, currently at 275.00, reflecting an increase of 4.5 (1.66%). This upward movement can be attributed to several factors. Over the past week, the stock has outperformed the benchmark Sensex, gaining 2.04% while the Sensex declined by 1.15%. Additionally, in the last month, Avience Biomedicals has shown a significant increase of 7.86%, contrasting with the Sensex's drop of 2.91%. <BR><BR>Today's performance indicates that the stock has outperformed its sector by 5.2%, suggesting strong relative strength. Furthermore, it is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which is typically a bullish signal for investors. However, it is important to note that there has been a decline in investor participation, with delivery volume falling by 7.77% against the 5-day average. Despite this decrease in participation, the stock remains liquid enough for trading, indicating that there is still interest in the stock.<BR><BR>Overall, the combination of positive performance relative to the market and sector, along with strong moving average positioning, contributes to the rise in Avience Biomedicals Ltd's stock price.

Who are the peers of the Avience Biomedi.?

Avience Biomedi.'s peers include Take, Bilcare, Aakaar Medical, Jeevan Scienti., Choksi Laborator, Star Imaging, and Aspira Pathlab. Bilcare has the highest 1-year return at 54.19%, while Aakaar Medical has the lowest at -26.26%.

Peers: The peers of Avience Biomedi. are Take, Bilcare, Aakaar Medical, Jeevan Scienti., Choksi Laborator, Star Imaging, Aspira Pathlab.<BR><BR>Quality Snapshot: Excellent management risk is observed at Aakaar Medical and Star Imaging, while Good management risk is found at Aakaar Medical. Below Average management risk is noted for Take, Bilcare, Jeevan Scienti., Choksi Laborator, Aspira Pathlab, and the rest. Growth is rated as Good for Aakaar Medical and Bilcare, while Below Average growth is seen in Take, Jeevan Scienti., Choksi Laborator, Star Imaging, Aspira Pathlab, and the rest. Capital Structure is rated as Excellent for Star Imaging, Good for Aakaar Medical, and Below Average for Take, Bilcare, Jeevan Scienti., Choksi Laborator, Aspira Pathlab, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Bilcare at 54.19%, while the peer with the lowest is Aakaar Medical at -26.26%. Avience Biomedi.'s 1-year return is not available for comparison. Additionally, Aakaar Medical has a negative six-month return of -19.46%.

What does Avience Biomedi. do?

Avience Biomedicals Ltd is a micro-cap healthcare services company, incorporated in December 2019 and converted to a public limited company in September 2024. It currently has no available revenue or profit data, with a market cap of INR 138 Cr and a P/E ratio of 16.00.

Overview: <BR>Avience Biomedicals Ltd operates in the healthcare services industry and is classified as a micro-cap company.<BR><BR>History: <BR>Avience Biomedicals Ltd was originally incorporated as a Private Limited Company on December 23, 2019. It later converted to a Public Limited Company, with its name changed to "Avience Biomedicals Limited," and received a fresh Certificate of Incorporation on September 3, 2024. Revenue and profit data are not available for any reporting period.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 138 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 16.00 <BR>Industry P/E: 107 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.83 <BR>Return on Equity: 27.86% <BR>Price-to-Book: 4.38 <BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

How big is Avience Biomedi.?

As of 14th August, Avience Biomedicals Ltd has a market capitalization of 137.00 Cr, classifying it as a Micro Cap, with no valid financial data available for Net Sales and Net Profit for the latest four quarters. The latest balance sheet shows Shareholder's Funds of 22.66 Cr and Total Assets of 56.41 Cr as of March 2025.

As of 14th August, <BR><BR>Market Cap: Avience Biomedicals Ltd has a market capitalization of 137.00 Cr, categorizing it as a Micro Cap.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales and Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The latest reporting period is March 2025, with Shareholder's Funds amounting to 22.66 Cr and Total Assets totaling 56.41 Cr.